Comparing Alecensa vs Xalkori
| Alecensa (alectinib) | Xalkori (crizotinib) |
|
|---|
| Alecensa (alectinib) | Xalkori (crizotinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Alecensa is a tyrosine kinase inhibitor that may be used to treat certain types of NSCLC that are caused by a mutation in the ALK gene. It is taken orally twice a day and may cause some serious side... View more |
Prescription only
Prescribed for Anaplastic Large Cell Lymphoma - ALK-Positive, Inflammatory Myofibroblastic Tumor, Non Small Cell Lung Cancer. Xalkori may also be used for purposes not listed in this medication guide. View more |
||||||||||||||||
| More about Alecensa (alectinib) | More about Xalkori (crizotinib) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Alecensa has an average rating of 9.5 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Xalkori has an average rating of 7.8 out of 10 from a total of 5 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Alecensa side effects |
View all Xalkori side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Alecensa prices |
View all Xalkori prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
33 hours |
42 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 121 drugs are known to interact with Alecensa:
|
A total of 817 drugs are known to interact with Xalkori:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
December 11, 2015 |
August 26, 2011 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.